Smith & Nephew New appointment & retirements of Non-Executive Directors

Medtech

Smith & Nephew Plc (LON:SN), the global medical technology business, has today announced the appointment of Rick Medlock as a Non-Executive Director.

Rick will join the Board and Audit Committee on 9 April 2020 at the conclusion of the Annual General Meeting. It is envisaged that Rick will replace Robin Freestone as Chair of the Audit Committee later in the year. Robin will remain on the Board in his capacity as Senior Independent Director.

Rick is a Non-Executive Director of Sophos plc, where he also chairs the Audit Committee and Risk Committee. He has more than 30 years’ experience of financial management in large international companies and was formerly Chief Financial Officer of Worldpay plc, Misys plc and Inmarsat plc.

Smith+Nephew also announces that Vinita Bali will be retiring as a Non-Executive Director at the end of 2020, on completion of 6 years’ service, and that Baroness Virginia Bottomley will also be retiring as a Non-Executive Director at the Annual General Meeting in April 2021, following completion of 9 years’ service.

Roberto Quarta, Chair of Smith+Nephew, said:

“I am delighted to welcome Rick Medlock to the Smith+Nephew Board. His extensive experience in both executive and non-executive finance leadership roles in global companies will strengthen our team. 

“I would also like to take the opportunity of thanking both Vinita and Virginia for their outstanding service to the Company. We look forward to their continuing contribution to the work of the Board over the coming months.”

Share on:

Latest Company News

Smith & Nephew CFO John Rogers to step down in September

Smith & Nephew has announced John Rogers will leave as chief financial officer, with Pierre Palassian appointed interim CFO until a successor is named.

Smith & Nephew and Imperial College London open surgical robotics innovation centre

Smith & Nephew and Imperial College London have launched a five-year partnership to accelerate research and innovation in robotic surgery.

Smith & Nephew maintains profit guidance as H1 trading margin improves

Smith & Nephew reported higher half-year revenue, operating profit and cash generation, while reducing full-year revenue guidance.

Smith & Nephew reports steady Q1 growth and confirms 2026 outlook

Underlying revenue grew 3.1% in Q1, supported by innovation and strong Sports Medicine performance. The company maintains its full-year targets and unveils a new $500m buyback program.

Smith & Nephew to host Surgeon Insights event in London

Smith & Nephew will host an investor event in London featuring US surgeons discussing innovation platforms across sports medicine, wound care, and orthopaedics, with presentations and Q&A sessions led by company leadership.

Smith & Nephew delivers higher profits and cash generation in 2025

Smith+Nephew reported full-year 2025 revenue of $6.16 billion, up 6.1% on a reported basis, with trading profit rising 15.5% and free cash flow increasing 52.5%.

    Search